Erlotinib is an oral EGFR tyrosine kinase inhibitor approved for treatment of lung and pancreas cancers with potential applications in pediatrics particularly for the treatment of malignant brain tumors over-expressing EGFR. The recommended erlotinib dose differs between pediatric and adult patients (125 mg/m²/day versus 90 mg/m²/day, respectively).
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Introduction
Erlotinib (Tarceva ® ) is an orally active, potent, and selective inhibitor of the epithelial growth factor receptor (EGFR) tyrosine kinase. From a pharmacokinetic point of view, erlotinib is metabolized by CYP3A4, CYP3A5, CYP1A1, and CYP1A2 isoforms of the P450 enzyme [1] . The main active metabolite OSI-420 is produced by O-demethylation of the side chains
and represents approximately 5% of the circulating erlotinib [2] . It has been suggested that erlotinib is a substrate of both ABCB1 (P-glycoprotein) and ABCG2 (BCRP) transporters [3, 4] . Erlotinib is registered for treatment of locally advanced or metastatic non-small cell lung cancer with stable disease after standard platinum-based first-line chemotherapy or after failure of at least one prior chemotherapy regimen, according to a daily dose of 150 mg per day [5] . Erlotinib is also indicated at a daily dose of 100 mg in combination with gemcitabine for the treatment of patients with metastatic pancreatic cancer [6] . Several promising preclinical studies have led to the exploration of its use in pediatrics, particularly in children with malignant brain tumors over-expressing EGFR [7, 8] . Broniscer et al. reported on erlotinib pharmacokinetics in plasma of an 8-year old child with glioblastoma treated with oral erlotinib and found it to be similar to that of published adult studies [9] . A Phase I study was set up with 46 children with refractory solid tumors treated with erlotinib alone or erlotinib and temozolomide [10] . The authors determined that the maximum tolerated dose (MTD) was 85 mg/m²/day, however significant interpatient variability in erlotinib disposition was also found at all dose levels. Another Phase I study in 23 patients with high-grade glioma aged 3 to 22 including erlotinib pharmacokinetics administered concurrently with radiotherapy found a much higher MTD of 120/mg/m²/day [11] . The authors found that the PK variables of erlotinib and OSI-420 were similar to those described in adults. A third multicenter phase I study was performed in order to establish the recommended dose of
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Author Manuscript Published OnlineFirst on June 8, 2011; DOI: 10.1158/1078-0432.CCR- erlotinib, when given alone or combined with radiotherapy to children with malignant brain tumors [12] . The recommended dose (125 mg/m²/day) was found to be the same for both treatment strata and is higher than that in adults (corresponding to around 90 mg/m²/day). The dosing of tyrosine kinase inhibitors has become an issue. Relationships between imatinib dose and efficacy have been observed in some subgroups of patients with gastrointestinal stromal tumors (GIST) defined according to c-Kit genotype [13] . However Delbaldo et al. found a wide dispersion of imatinib plasma concentrations in 34 patients with advanced GIST receiving the same dose, with no relationship between imatinib exposure and response rate or between total or free unbound imatinib and clinical activity, but a positive correlation between exposure and hematologic toxicity [14] . Other studies described close relationships between plasma imatinib concentrations and both efficacy and toxicity in patients with either chronic myeloid leukemia [15, 16] or GIST [17, 18] . Similar relationships have been observed for sunitinib [19] .
The aim of this pharmacokinetic-pharmacodynamic (PK-PD) analysis was to evaluate the pharmacological characteristics of erlotinib in paediatric patients compared to those in adult patients. The adult pharmacokinetic data was provided by a neoadjuvant pilot study performed in patients with head and neck carcinoma [20, 21] and the pediatric data come from a phase 1 study in children with malignant brain tumors [12] . First, both datasets were combined to evaluate PK characteristics. Secondly, relationships between individual pharmacokinetic parameters, such as erlotinib plasma exposure, and adverse events were examined in order to compare child and adult patients' pharmacodynamic sensitivity to the drug. 
Patients
Adult patients (n = 42) with non-metastatic head and neck tumors awaiting surgical resection were enrolled in a clinical trial. The study design and eligibility criteria have been described previously in detail [20] . Patients were treated with erlotinib at 150 mg/day for a variable period corresponding to the time between pan-endoscopy and surgical resection. In the event of grade 2 or more diarrhea or skin rash that were symptomatically unacceptable to the patient, treatment was withheld until resolution to grade 1, and then erlotinib was restarted at a dose of 100 mg/day. If toxicity reoccurred, erlotinib was stopped.
Fifty young patients (age range 2 to 19 years) with malignant brain tumors were included within a multicenter, dose escalation phase I study (NCT00418327; ITCC-003/MO18461) of the Innovative Therapies with Children with Cancer (ITCC) European Consortium. Children with histologically/cytologically confirmed malignant brain tumors refractory to, or relapsing after, first line therapy, for which no effective treatment exists, were enrolled into Group 1 (erlotinib alone). Children with newly diagnosed, histologically confirmed brainstem glioma were enrolled into Group 2 (erlotinib and radiotherapy). Eligibility criteria are described in the article reporting the clinical results [12] . Erlotinib tablets were administered orally once daily in 3-week cycles at four dose levels; 1 = 75 mg/m 2 , 2 = 100 mg/m 2 , 3 = 125 mg/m 2 , 4 = 150 mg/m 2 . According to the recommendations for the conduct of phase I trials in children with cancer [22] , the starting dose was approximately 80% of the adult recommended dose (RD) (150 mg/day). In Group 2, patients received local irradiation to the brainstem region of 54 Gy over 6 weeks (1.8 Gy/fraction/day). The first erlotinib dose was administered within 4
hours of the first irradiation. Conventional 3+3 dose escalation methodology was used for Group 1 [23] , with an extension of 10 patients at the RD. In Group 2, dose escalation decisions were made using a continual reassessment method with likelihood based inference 
Pharmacokinetic study
Blood sampling and mass spectrometry analysis. Serial blood samples were taken at various intervals to determine the pharmacokinetic profile of erlotinib and its principal metabolite (OSI-420). For adults, on day 1 of the treatment, three blood samples were collected from each patient: before erlotinib administration, 2 hours and 4 to 8 hours after the dose. Patients were clinically evaluated at a median time of 14 days after starting the treatment and one blood sample 24 hours after the last administration was obtained. On the day preceding, and the day of the surgery, two additional samples were collected (6-8 hours and approximately 24 hours, respectively, after the last administration of erlotinib).
For children and young adults, plasma samples were collected before drug intake at day 1, 30 minutes, 1, 2, 4, 6, 8, and 24 hours after the erlotinib dose at day 8 and day 22 for group 1 and at day 8 and day 43 (end of irradiation) for group 2.
For both children and adults, blood samples were centrifuged (1500g, 15 min, 4°C), the plasma frozen at -20°C until analysis and the determination of plasma erlotinib and OSI-420
Research. [25] . The calibration range was 1-3000 ng/ml for erlotinib and 1-1000 ng/ml for OSI-420.
Genetic analysis.
A blood sample was collected on day 1 for pharmacogenetic investigation.
Genomic DNA was extracted from peripheral blood leukocytes according to standard procedures with QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturer's instructions. Genotyping was done for 5 single-nucleotide polymorphisms (SNP). ABCB1 variants (2677G>T, 2677G>A and 3435C>T) were determined by PCR-RFLP as previously described [26, 27] . ABCG2 421C>A variant was determined by polymerase chain reaction (PCR) and direct sequencing as published before [21] . The presence of CYP3A5*1/CYP3A5*3 alleles was determined on genomic DNA with allele specific real time PCR as previously described [28] . Whenever genetic data was missing, genotypes were randomly assigned according to the frequency of the genotypes in the remaining study population. Box plots of clearance values were examined to verify that this attribution did not change the population clearance distribution.
Population pharmacokinetic analysis. Plasma erlotinib and OSI-420 concentrations were analyzed according to a nonlinear mixed effects approach using the NONMEM program (version VI, level 1.0, Icon Development Solutions running on an Intel Core 2 Quad) according to a one-compartment pharmacokinetic model for erlotinib and to a twocompartment pharmacokinetic model when both erlotinib and OSI-420 were analyzed and using the first-order conditional estimation (FOCE) method [21] . A proportional error model was used for both inter-patient and residual variability. 
Determination of individual pharmacokinetic parameters and covariate analyses.
The influence of the following variables on pharmacokinetic parameters was examined: body weight, sex (0 for male, 1 for female), age, population (POP=0 for adults and POP=1 for children), albuminemia, plasma AGP level, ALAT concentration, effect of simultaneous administration of enzymatic inducers (carbamazepine, phenytoine, dexamethasone, prednisone, prednisolone), genotype for ABCB1 (2677G>T/A and 3435C>T), ABCG2 (421C>A) and CYP3A5 (6986G>A). Moreover, interoccasion variability (IOV) was tested on all the parameters because data from 2 cycles were analyzed simultaneously. The first occasion was defined as the samples of cycle 1 (i.e. day 1 and day 8 for children) and the second occasion as those of cycle 2 (i.e. day 22 for group 1 patients) or cycle 3 (i.e. day 43 for group 2 patients). There was no IOV for adults since they only received one cycle of erlotinib. 
Pharmacokinetic / pharmacodynamic relationship.
Systemic exposure to erlotinib was calculated using individual post hoc clearance: AUC = dose/CL for erlotinib. Relationship between AUC at day 1 (i.e., dose/CL at day 1) and skin toxicity at the mid-term treatment visit was evaluated in children and was compared to the relationship previously observed in adults [21] . Toxicity (i.e. skin rash, folliculitis, acne, and pruritis) was evaluated at the mid-term treatment visit and graded using the National Cancer Institute Common Toxicity Criteria, version 2.0 or 3.0. The relationship between initial daily AUC and skin toxicity grade was examined using a four-level ordered logistic regression for adults (with skin toxicity graded 0-3) and using a three-level ordered logistic regression for children (with skin toxicity graded 0, 1 and 2/3 (grades 2 and 3 were grouped as only 3 children developed a grade 3 skin toxicity)). Based on this model, the cumulative-predicted probabilities of skin toxicity according to AUC were obtained and represented as curves. The analyses were performed using Stata version 10.0, Stata Co, College Station, TX, USA.
Research. 
Determination of cut-off point of erlotinib AUC.
Receiver operating characteristic (ROC) curves were constructed to examine the value of an erlotinib AUC threshold predicting a minimum skin toxicity of grade 2. The area under ROC curves of erlotinib AUC both in children and in adults for the prediction of a minimum skin toxicity of grade 2 were calculated. The diagnostic accuracy values of sensitivity (SE) and specificity (SP) were determined. The optimal cut-off value was obtained. The analyses were performed using Stata version 10.0, Stata Co, College Station, TX, USA.
RESULTS
Patients
Forty-two adults were assessable for pharmacokinetic investigations and plasma samples of Complete pharmacogenetic data were available for 79 (42 adults and 37 children) of the 88 patients. Minor allele frequencies are given in Table 1 (footnote). The genotypes did not depart significantly from Hardy-Weinberg equilibrium (exact tests non-significant in all four cases p>0.10). The patients' characteristics at baseline are summarized in Table 1 .
Determination of individual pharmacokinetic parameters and covariate analyses
Erlotinib pharmacokinetics were adequately described by a one-compartment model with first-order absorption and first-order elimination. The corresponding pharmacokinetic variables were CL/F (apparent total plasma clearance of erlotinib), V/F (apparent volume of distribution of erlotinib) and Ka (absorption rate constant). The pharmacokinetic model
Research. 2677G>T/A was associated with a 19% decrease in CL whereas the presence of a CYP3A5*1 allele was associated with a 42% increase in CL. For V/F, body weight was the only significant (p < 0.001) covariate associated with a decrease in inter-individual variability (IIV) from 56.6% (no covariate) to 13%. The final covariate models are detailed in Table 2 .
Of note, substantial interoccasion variability was observed for CL/F and V/F (22% and 46%, respectively). The residual variability was 31.9% for erlotinib concentrations. (Table 2) . A sensitivity analysis excluding the 9 patients for which the pharmacogenetic data was incomplete was conducted in order to test the robustness of the model and all covariates found in the final model remained significant (p < 0.001) (data not shown). The proportion of circulating active metabolite OSI-420 compared to erlotinib, calculated using AUCmetabolite / (AUCmetabolite + AUCerlotinib), was 8.1% (SD=3.2%).
Regarding the discrepancy between the recommended doses in adults and children (90 and 125 mg/m²/day, respectively), the impact of the covariate POP on the pharmacokinetic model was carefully evaluated. The typical value of erlotinib clearance was 27% lower (p < 0.001) in children when POP was the only considered covariate, and 24% higher (p < 0.025) if POP was considered together with body weight ( 
Performance of final pharmacokinetic model
This final model adequately described erlotinib and OSI-420 pharmacokinetic profiles as
shown by the goodness-of-fit plots ( Fig. 1 ) and by VPC (Fig. 2) .
PK/PD relationships
The relationship between drug exposure and the severity of skin toxicity was examined. The box plot in Fig.3 shows an increase in AUC with increasing grade of toxicity in both children and adults. This positive association between exposure and toxicity was significant in the four-level ordered logistic regression analysis for adults (p = 0.014) (13) and a trend is observed in the three-level ordered logistic regression analysis for children (p = 0.06). Fig. 4 shows the cumulative probabilities of having skin toxicity according to AUC using the probabilities predicted by the ordered logistic regression models (adult data analyzed with the model previously published (13) and children data analyzed with the present model). There is within each population, adults or children, a strong PK/PD relationship, which seems very similar. It is noteworthy that skin toxicity was not significantly correlated with trough erlotinib plasma levels observed at steady-state (data no shown).
Determination of a cut-off of erlotinib AUC
Using the ROC curve, the AUC threshold predicting a minimum skin toxicity of grade 2 was 27 ng.mL.h 
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DISCUSSION
Pharmacokinetic-pharmacodynamic (PK-PD) studies combining children and adults are scarce [29, 30] . This PK-PD analysis performed on data from two independent clinical trials contributes important information towards explaining the observed difference in erlotinib tolerance between pediatric and adult patients (i.e., daily recommended dose of 125 mg/m² vs.
150 mg corresponding to approximately 90 mg/m², respectively).
Although the skin symptoms were rather different between children and adults, the relationship between daily erlotinib AUC and the probability of skin toxicity was very consistent between the two subgroups. Previous phase I studies in children concluded that erlotinib and OSI-420 pharmacokinetics values were similar to those in adults [11, 31] .
However, in our study significant differences in pharmacokinetics were observed between children and adults. By considering the covariate POP (i.e., POP=1 for children or POP=0 for adults) alone or in combination with other covariates, the population approach applied to this dataset revealed and quantified this difference. A higher mean value of erlotinib clearance (i.e., + 54%) was observed in children compared to adults when expressed in L.h -1 .kg -1 .
Comparison of the individual POSTHOC values confirmed this higher elimination capacity in children: CL = 0.146 ± 0.070 L.h -1 .kg -1 for children versus CL = 0.095 ± 0.045 L.h -1 .kg -1 for adults. This pharmacokinetic particularity explains why the recommended dose in children is higher than in adults. The lack of data prevented us from including smoking status as a covariate in our study. However, a large proportion of the adults smoked (55%) whereas one can assume most of the children did not, which makes the higher clearance in children particularly remarkable and unexpected, as one can assume that the adults' clearance is increased due to the large proportion of smokers in that population. Specific consideration of
the adolescents showed that their mean erlotinib clearance was higher than that in children younger than 12 years old, and was similar to that in adults. However, it is interesting to note that by adding the covariate POP to the final covariate model (i.e., which included body weight, ALAT, CYP, and ABCB1 (2677G>T/A)), the typical value of CL was only 11% higher in pediatrics (versus 24% when only the POP covariate is considered). This result showed that the final covariate model explains most of the difference between the two subgroups.
The erlotinib and OSI-420 clearance were negatively correlated with ALAT. An increase of this covariate might be the reflection of hepatic dysfunction which leads to a decrease in erlotinib and OSI-420 clearance. The impact of hepatic dysfunction on erlotinib clearance has been confirmed in a clinical study using a more conventional approach [32] .
Our results also highlight the relevance of taking into account pharmacogenetic information for erlotinib pharmacokinetics analysis. By analyzing children and adults together, we found that carriers of at least one allele *1 of CYP3A5 had a 1.4 times higher clearance than patients harboring the CYP3A5 *3/*3 genotype (which represents about 80% in Caucasians [33] ).
This observation is in agreement with the functional consequence of the 6986G>A SNP (allele CYP3A5*3), which encodes an aberrantly spliced mRNA with a premature stop codon, leading to the absence of the protein [34] . A similar trend was observed for ABCB1 2677 G>T/A SNP. Although a recent work suggested that OSI-420, but not erlotinib, is a substrate for ABCB1 [35] , the presence of one variant allele (T or A) was associated with an average 20% decrease of the clearance of both erlotinib and OSI-420, suggesting the role of ABCB1 in erlotinib elimination as described in another study [36] .
These results confirm the relationship between plasma concentrations of tyrosine kinase inhibitors and their dose limiting toxicity. Besides, it has been suggested that patients experiencing skin rash during erlotinib treatment have an improved survival and rash has been proposed as a surrogate marker for favorable outcome [37] . The correlation observed between exposure and rash in both adults and children and the previously observed relationship between rash and efficacy strongly supports the existence of an exposure/response correlation in addition to efficacy observed in EGFR amplified and mutant tumours [38, 39] . There is now a need to evaluate the benefit of therapeutic drug monitoring in patients treated with erlotinib. The methodology we used here, consisting in AUC calculation from pharmacokinetic data processed with population pharmacokinetics followed by a ROC analysis to determine the cut-off AUC, is a reasonable approach. Due to the heterogeneity between patients in terms of disease, it was not possible to examine the relationship between AUC and clinical response. Because previous clinical studies conducted with erlotinib in lung and pancreas cancer showed that a grade 2 rash was associated with a better outcome [37] , we chose to determine the cut-off AUC associated with a grade 2 rash which is a surrogate marker for efficacy. In this study, we found a cut-off AUC of 27 ng/ml/h but further studies with larger datasets and in other groups of patients treated with erlotinib (e.g. lung cancer patients) are necessary in order to determine optimal cut-off values and subsequently suggest their use in prospective clinical studies.
In conclusion, this analysis of combined data from two clinical trials demonstrated that the higher recommended dose in children (125 mg/m²/day) than in adults (90 mg/m²/day) is mainly due to pharmacokinetic rather than pharmacodynamic particularities. 
